Ross M. Maltz, MD

Articles by Ross M. Maltz, MD

The Biosimilar Shift: Trending Infliximab Biosimilar Utilization and Associated Cost Savings for Commercial Insurance

BySamantha R. Paglinco, DO,Mahmoud Abdel-Rasoul, MS, MPH,Megan McNicol, PharmD, BCACP,Morgane C. Mouslim, DVM, ScM,Brendan Boyle, MD,Jennifer L. Dotson, MD, MPH,Hilary K. Michel, MD,Ross M. Maltz, MD

October 14th 2025

Infliximab biosimilars created price competition causing insurance claims costs for infliximab originator and infliximab biosimilars to decrease, generating significant savings to the health care system.

Ross M. Maltz, MD

Articles by Ross M. Maltz, MD

The Biosimilar Shift: Trending Infliximab Biosimilar Utilization and Associated Cost Savings for Commercial Insurance

Latest Updated Articles

Trending on AJMC

Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled

FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease

Value-Based Care Offers Solutions to Patient Access Challenges: Brian Mulherin, MD

New WHO Reports Sounds Alarm on Antimicrobial Resistance

Pediatric Atopic Dermatitis Treatment Selection: Biologics vs Nonsteroidal Topical Therapies